Hematologic profiles with bortezomib in relapsed MM

被引：0
|
作者：
Lonial, S.
Richardson, P. G.
Miguel, J. San
Sonneveld, P.
Schuster, M.
Blade, J.
Cavenagh, J.
Rajkumar, V.
Jakubowiak, A.
Esseltine, D.
Anderson, K. C.
Harousseau, J.
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Hosp Univ Salamanca, Salamanca, Spain
[4] Univ Rotterdam Hosp, Rotterdam, Netherlands
[5] NY Presbyterian Hosp, New York, NY USA
[6] Univ Barcelona, Barcelona, Spain
[7] St Bartholomews Hosp, London, England
[8] Mayo Clin, Rochester, MN USA
[9] Univ Michigan, Ann Arbor, MI 48109 USA
[10] Millennium Pharmaceut Inc, Cambridge, MA USA
[11] Hop Hotel Dieu, Nantes, France
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
MULTIPLE-MYELOMA; REFRACTORY MYELOMA; PHASE-2;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：159 / 160
页数：2
相关论文
共 50 条
  • [1] Vorinostat and Bortezomib in Relapsed/Refractory MM
    Weber, D. M.
    Badros, A.
    Jagannath, S.
    Siegel, D.
    Richon, V.
    Rizvi, S.
    Garcia-Vargas, J.
    Reiser, D.
    Anderson, K. C.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S42 - S42
  • [2] Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
    Jakubowiak, Andrzej
    Offidani, Massimo
    Pegourie, Brigitte
    De La Rubia, Javier
    Garderet, Laurent
    Laribi, Kamel
    Bosi, Alberto
    Marasca, Roberto
    Laubach, Jacob
    Mohrbacher, Ann
    Carella, Angelo Michele
    Singhal, Anil K.
    Tsao, L. Claire
    Lynch, Mark
    Bleickardt, Eric
    Jou, Ying-Ming
    Robbins, Michael
    Palumbo, Antonio
    BLOOD, 2016, 127 (23) : 2833 - 2840
  • [3] Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis
    Lee, Sarah S.
    Rosko, Nathaniel
    Patel, Bhumika J.
    Waldron, Madeline
    Tomer, Jackie
    Goldman, Roman
    Karam, Mary Ann
    Reed, Janice
    Faiman, Beth M.
    Hamilton, Kimberly
    Mathur, Saveta
    Samaras, Christy J.
    Valent, Jason
    BLOOD, 2018, 132
  • [4] Prospective evaluation of the bone anabolic effect of bortezomib in relapsed multiple myeloma (MM) patients
    Zangari, Maurizio
    Cavallo, Federica
    Suva, Larry
    Dilley, Joshua
    Trico, Guido
    Barlogie, Bart
    Burns, Michael J.
    Passera, Roberto
    Boccadoro, Mario
    Esseltine, Dixie
    Yaccoby, Shmuel
    BLOOD, 2007, 110 (11) : 798A - 798A
  • [5] Bortezomib in patients with relapsed-refractory multiple myeloma (MM). Clinical observations.
    Kyrtsonis, MC
    Sachanas, S
    Vassilakopoulos, TP
    Kafassi, N
    Tzenou, T
    Papadogiannis, A
    Kalpadakis, C
    Antoniadis, AG
    Dimopoulou, MN
    Angelopoulou, MK
    Siakantaris, MP
    Dimitriadou, EM
    Kokoris, SI
    Plata, E
    Tsaftaridis, P
    Panayiotidis, P
    Pangalis, GA
    BLOOD, 2005, 106 (11) : 382B - 382B
  • [6] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    BLOOD, 2014, 124 (21)
  • [7] Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
    Moreau, Philippe
    Chanan-Khan, Asher
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Punnoose, Elizabeth A.
    Cordero, Jaclyn
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed Hamed
    Freise, Kevin J.
    Leverson, Joel D.
    Enschede, Sari Heitner
    Ross, Jeremy A.
    Maciag, Paulo C.
    Verdugo, Maria
    Harrison, Simon J.
    BLOOD, 2017, 130 (22) : 2392 - 2400
  • [8] Pharmacokinetic (PK) and pharmacodynamic (PD) profiles of bortezomib (B) in patients (pts) with relapsed multiple myeloma (MM): A phase I/II study in Japan.
    Tobinai, Kensei
    Watanabe, Takashi
    Ogawa, Yoshiaki
    Ogura, Michinori
    Morishima, Yasuo
    Minami, Hironobu
    Itoh, Kuniaki
    Hotta, Tomomitsu
    BLOOD, 2006, 108 (11) : 365B - 366B
  • [9] 3D Telomeric Profiles of MGUS, MMN and Relapsed MM
    Olujohungbe, Ade B.
    Klewes, Ludger R.
    Rubinger, Morel
    Mai, Sabine
    BLOOD, 2011, 118 (21) : 1251 - 1251
  • [10] Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
    Anderson, K. C.
    Jagannath, S.
    Jakubowiak, A.
    Lonial, S.
    Raje, N.
    Schlossman, R.
    Munshi, N.
    Knight, R.
    Esseltine, D.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345